DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ATACAND
Clinical Trials for Atacand
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00150631 | Danish Hypertension Prevention Project - DHYPP | Unknown status | AstraZeneca | Phase 3 | The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year. Then, treatment is withdrawn and the subjects is followed for 10 years to determine if the treatment has been able to either prevent or delay the development of hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass. |
| NCT00150631 | Danish Hypertension Prevention Project - DHYPP | Unknown status | University of Aarhus | Phase 3 | The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year. Then, treatment is withdrawn and the subjects is followed for 10 years to determine if the treatment has been able to either prevent or delay the development of hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass. |
| NCT00150631 | Danish Hypertension Prevention Project - DHYPP | Unknown status | Karin Skov | Phase 3 | The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year. Then, treatment is withdrawn and the subjects is followed for 10 years to determine if the treatment has been able to either prevent or delay the development of hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass. |
| NCT00242346 | High Doses of Candesartan Cilexetil on the Reduction of Proteinuria | Completed | AstraZeneca | Phase 3 | The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Atacand
Condition Name
Condition MeSH
Clinical Trial Locations for Atacand
Trials by Country
Clinical Trial Progress for Atacand
Clinical Trial Phase
Clinical Trial Sponsors for Atacand
Sponsor Name
